#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Phaeochromocytoma Palmar-plantar erythrodysaesthesia syndrome Splenic marginal zone lymphoma Pseudomyxoma peritonei Primary hyperoxaluria Angiosarcoma Osteosarcoma metastatic Congenital megacolon Restless legs syndrome Progressive familial intrahepatic cholestasis Hepatobiliary cancer Langerhans' cell histiocytosis Congenital pseudarthrosis Cerebral haemorrhage Oesophageal adenocarcinoma stage III More trials…

    Learn about Rare Diseases

    Basal cell naevus syndrome – Life with Disease Pulmonary sarcoidosis – Diagnostics Cytokine release syndrome – Diagnostics Hereditary neuropathic amyloidosis – Treatment Primary biliary cholangitis – Treatment Netherton’s syndrome – Basic Information Waldenstrom’s macroglobulinaemia – Life with Disease IgA nephropathy Nodal marginal zone B-cell lymphoma – Trials in Disease Usher’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Aluminium Oxide, Hydrated Milademetan Sulpiride Alrefimotide Meropenem Mocravimod Pyridoxine Hydrochloride Bp DUVELISIB Phleum Pratense Capivasertib THEOPHYLLINE ANHYDROUS Ferric Derisomaltose Nebivolol Db-Oto-3 IDP-121 Aliskiren Ebastine Fremanezumab Fusidic Acid Fluasterone More therapies…

    Learn about Your Condition

    Vitamin D deficiency Cardiogenic shock Giardiasis Tooth loss Pancreatitis acute Toxicity to various agents Endocarditis Myasthenia gravis Malignant oligodendroglioma Cutaneous T-cell lymphoma Fibromyalgia Vesicoureteric reflux Thrombolysis Lung transplant Primary amyloidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ict01
    • Pembrolizumab
    Belgium France Germany Spain

  • Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Multiple system atrophy
    • Parkinson’s disease
    Investigated Drugs:
    • Exidavnemab
    Poland Spain

  • Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
    Investigated Drugs:
    • Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
    France Hungary Italy Spain Sweden

  • Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Loperamide
    • Capecitabine
    • Oxaliplatin
    Belgium Estonia France Germany Greece Ireland +6

  • Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Tazemetostat
    • Vincristine
    • Cyclophosphamide
    Belgium France

  • Trial of Ataluren for Severe Common Variable Immunodeficiency with Autoimmunity in Patients with LRBA Deficiency

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ataluren
    Belgium
Previous Page
1 … 1,664 1,665 1,666 1,667 1,668 … 1,673
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!